Navigation Links
2011 Prix Galien USA Final Candidates Announced: Competing for Best Biotechnology Product and Best Pharmaceutical Agent
Date:7/21/2011

NEW YORK, July 21, 2011 /PRNewswire/ -- Honoring biomedical advances impacting both individual lives and public health in the past decade, the Prix Galien USA committee today announced the 2011 final candidates for the 5th annual Prix Galien Awards competition. The Prix Galien Award recognizes the technical, scientific and clinical research skills necessary to develop innovative medicines and devices, and is considered the industry's highest accolade.

Final candidates for the Prix Galien USA 2011 Awards are: Amgen (Prolia®)Janssen Biotech Inc. (Stelara™) Boehringer Ingelheim (Pradaxa®)Merck (Emend®)Cubist (Cubicin®) Merck (Zetia®)Dendreon (Provenge®)Novartis (Gilenya®) Eisai (Banzel®)Pfizer (Prevnar 13®)GlaxoSmithKline (Arzerra™)"Pharmaceutical research and development advances the human condition through the development of novel therapies and cures," said Gerald Weissmann, M.D., Prix Galien USA committee chair, New York University professor emeritus and editor-in-chief of The FASEB Journal. "This year's candidates demonstrate the positive impact biomedical discovery and innovation can have on improving lives of individuals."

As in past years, the committee will judge candidates as Best Pharmaceutical Agent and Best Biotechnology Product approved by the U.S. Food and Drug Administration (FDA) during the past 10 years.

"Prix Galien salutes the major contributions of the scientists and researchers who devote their lives to the development of treatments in the continuous quest to improve the health of the world's population," said Elie Wiesel, Nobel Laureate and Prix Galien USA committee member.

2011 candidates range from a vaccine to protect babies from seven strains of pneumococcal bacteria to the first oral drug therapy for relapsing forms of multiple sclerosis.  In 2010, the Prix Galien USA committee honored life sciences companies for innovations such as therapies for rare genetic disorders and diagnostic tests to indentify infections.  Last year's honorees include Luminex Corporation (xTAG ®), Novartis (Coartem®) and Merck & Co. (RotaTeq®).

The Award Ceremony, held at the Museum of Natural History in New York City, September 27, 2011, is among the most prestigious prizes for biopharmaceutical research and development.  The Prix Galien USA award committee comprises 11 individuals including Nobel Laureates, founders of major biotech companies and editors of world-renowned biology journals.  Prix Galien was first established in 1970 by French pharmacist Roland Mehl and was inaugurated in the United States in September 2007.

For details about the Prix Galien - USA award and committee, visit www.galienfoundation.org

AWARDS COMMITTEE

MICHAEL S. BROWN, M.D.*
UT Southwestern Medical Center at Dallas

WALTER GILBERT, PH.D.*
Harvard University

JOSEPH GOLDSTEIN, M.D.*
UT Southwestern Medical Center at Dallas

PAUL GREENGARD, PH.D.*
Rockefeller University

ERIC R. KANDEL, M.D.*
Columbia University

RICHARD A. LERNER, M.D.
Scripps Research Institute

PAUL A. MARKS, M.D.
Memorial Sloan Kettering Cancer Center

BENGT SAMUELSSON, M.D., PH.D.*
Nobel Foundation, Karolinska Institute

JAN T. VILCEK, M.D.
New York University School of Medicine

ELIE WIESEL*
Honorary Member, Boston University

GERALD WEISSMANN, M.D.
New York University School of Medicine Committee Chairman

*Nobel Laureate

The Galien Foundation is a not-for-profit, 501(c)(3) public charity. Contributions are tax deductible as provided by law.

CONTACT:  Mary Heather, Porter Novelli for Prix Galien USA, +1-212-601-8153


'/>"/>

SOURCE Prix Galien USA
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Porter Novelli Named Agency of Record for Prix Galien USA Awards
2. Luminex Corporation Wins Prestigious 2010 Prix Galien USA Award
3. 2010 Prix Galien USA Pro Bono Humanum Award to be Presented to UNITAID for Work In Global HIV/AIDS Effort
4. Prix Galien USA Honors Innovation in Science and Biotech Industries
5. Amgen and UCB Team Up With NASA on Final Space Shuttle Mission to Conduct Preclinical Test of Sclerostin Antibody on Bone Loss
6. Glycotex, Inc. Releases Final Phase II Clinical Trials Results in the Clinicaltrials.gov Database and Announces the Results of the Mechanism of Action Study for its Product Candidate GLYC-101
7. Next-Generation Pharmacist™ Awards Program Announces 2011 Finalists
8. Dr. Jay Yadav, CardioMEMS Founder & CEO, Selected as a Finalist for 2011 Business Person of the Year Award
9. Final Published Trial Data in The Lancet Supports Safety and Effectiveness of MicroVention-Terumos HydroCoil® Embolic System for Treatment of Cerebral Aneurysms
10. Millennium Laboratories Founder and CEO James Slattery Named Ernst & Young Entrepreneur of the Year® San Diego Finalist
11. CardioMEMS Founder & CEO Dr. Jay Yadav Named Ernst & Young Entrepreneur of the Year Finalist
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... , Oct. 11, 2017  Caris Life Sciences ® ... fulfilling the promise of precision medicine, today announced that ... Caris, Precision Oncology Alliance™ (POA) as its 17 th ... the St. Jude Crosson Cancer Institute will help develop ... use of tumor profiling, making cancer treatment more precise ...
(Date:10/10/2017)... 10, 2017  NDS received FDA 510(k) clearance in May 2017 ... display stand specifically designed for endoscopy environments. An innovative secondary monitor ... clinical solution to support the improvement of patient outcomes, procedural efficiency, ... ... ...
(Date:10/5/2017)... , Oct. 5, 2017  In response to ... Oral and Maxillofacial Surgeons (AAOMS) released prescribing recommendations ... to be used as a first-line therapy to ... Recognizing the value ... White Paper "Opioid Prescribing: Acute and Postoperative Pain ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 million ... by frequent cessation in breathing. Oral appliances can offer significant relief to about ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... to meet the demand of today’s consumer and regulatory authorities worldwide. From Children’s ... experts and tested to meet the highest standard. , These products are ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical ... Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. ... honor of Morris F. Collen, a pioneer in the field of medical informatics, this ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information ... we intend to develop to enable prevention of a major side effect of ... loss, especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a ... of a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners ... October 11, 2017. , The annual award competition recognizes editorial and design excellence across ...
Breaking Medicine News(10 mins):